Curcumin and Methotrexate: A Promising Combination for Osteosarcoma Treatment via Hedgehog Pathway Inhibition
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252011300 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Giulia Giliberti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Napoli, Italy. Hauptthemen laut MEDLINE: Osteosarcoma, Methotrexate, Hedgehog Proteins, Signal Transduction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dello Sviluppo Economico (MISE).
Abstract (Originalsprache)
Osteosarcoma (OS) is the most severe bone tumor in children. A chemotherapy regimen includes a combination of high-dose Methotrexate (MTX), doxorubicin, and cisplatin. These drugs cause acute and chronic side effects, such as infections, thrombocytopenia, neutropenia, DNA damage, and inflammation. Therefore, to identify new therapeutic strategies, effective and with a safety profile, is necessary. The Hedgehog (Hh) signaling pathway involved in tumorigenesis is active in OS. Hh components Patched receptor 1 (PTCH1), Smoothened (SMO), and glioma-associated oncogene homolog transcription factors (GLI1 and GLI2) are overexpressed in OS cell lines and patient samples. Curcumin (CUR)—with antioxidant and anti-cancer properties—downregulates Hh components in cancer, inhibiting progression. This study investigates CUR effects on the MG-63 OS cell line, alone and combined with MTX, to propose a novel therapeutic approach. Our study suggests CUR as a novel therapeutic agent in OS, particularly when combined with MTX. Targeting the Hh signaling pathway, CUR and MTX showed significant pro-apoptotic effects, increasing the BAX/Bcl-2 ratio and total apoptotic cell percentage. They reduced the expression of Hh pathway components (PTCH1, SMO, GLI1, and GLI2), inhibiting OS cell proliferation, survival, and invasion. CUR and MTX combined determined a β-Catenin decrease and a trend toward reducing NF-kB and matrix metalloproteinases (MMP-2 and MMP-9). Our findings suggest CUR as a support to OS treatment, improving outcomes and reducing the adverse effects of current therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Napoli, Italy.
- Department of Woman, Child and General and Specialist Surgery, University of Campania "Luigi Vanvitelli", 80138 Napoli, Italy.
- Department of Life Sciences, Health and Health Professions, Link Campus University, 00165 Rome, Italy.
ORCID-Profile: Daniela Di Pinto
Förderung
- Ministero dello Sviluppo Economico (MISE)
Zitieren
APA
Giliberti, G., Marrapodi, M. M., Di Feo, G., Pota, E., Di Martino, M., Di Pinto, D., Rossi, F., & Di Paola, A. (2024). Curcumin and Methotrexate: A Promising Combination for Osteosarcoma Treatment via Hedgehog Pathway Inhibition. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252011300
Vancouver
Giliberti G, Marrapodi MM, Di Feo G, Pota E, Di Martino M, Di Pinto D, et al. Curcumin and Methotrexate: A Promising Combination for Osteosarcoma Treatment via Hedgehog Pathway Inhibition. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252011300
BibTeX
@article{Giliberti2024,
author = {Giliberti, Giulia and Marrapodi, Maria Maddalena and Di Feo, Giuseppe and Pota, Elvira and Di Martino, Martina and Di Pinto, Daniela and Rossi, Francesca and Di Paola, Alessandra},
title = {Curcumin and Methotrexate: A Promising Combination for Osteosarcoma Treatment via Hedgehog Pathway Inhibition},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252011300}
}
EUVIMED